Empliciti (elotuzumab) / AbbVie, BMS - LARVOL DELTA

Comprehensive cost analysis of 4th line + therapies for relapsed/refractory multiple myeloma in Germany: Drug, co-medication, and office-based treatment perspective (ASH 2025) - "Whilst there is no official myeloma registry in Germany, treatments we considered were reimbursable combination therapies frequently used in the 4 th line treatment of RRMM in Germany in 2023, containing: carfilzomib, daratumumab, elotuzumab, melflufen, selinexor, talquetamab and teclistamab, and newly approved therapeutic options like elranatamab, along with evidence-based recommendations regarding premedication, comedication, and mandatory prophylaxis of treatment-related adverse events, as outlined in the Summary of Product Characteristics (SmPC) and published literature... Costs for myeloma drugs and combinations show a broad variation, from 88.863€ for Elotuzumab/Revlimid/Dexamethasone (ERd), to 178.850€ for talquetamab treatment. The second lowest in terms of annual costs was melflufen with 106.839€, followed by Elotuzumab/Pomalidomide/Dexamethasone (EPd):119.301€, teclistamab: 124.626€, Selinexor/Dexamethasone (Sd): 129.976€, elranatamab: 146.706€ and..."

Cost-analysis • HEOR • Hematological Malignancies • Multiple Myeloma

Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study (ASH 2025) - "Novel BCMA-targeted therapies, such as CAR T-cells (cilta-cel from 2nd line, ide-cel from 3rd line) and bispecific T-cell engagers (e.g., teclistamab, elranatamab from 4th line), have become new standards of care...Abbreviations: K=carfilzomib; E=elotuzumab; Pom=pomalidomide; d=dexamethasone; Isa=isatuximab; F=panobinostat; R=lenalidomide; Tec=teclistamab; X=selinexor; Elra=elranatamab; Belamaf=belantamab mafodotin; Ixa=ixazomib... This real-world study of 100 MM patients relapsing after anti-BCMA CAR T-cell treatment shows that 91% were in their 4th or 5th line of therapy. A large majority were triple-class exposed, and 52% were lenalidomide-refractory. In the absence of a clear standard of care, common treatments were identified: elotuzumab- and isatuximab-based regimens in the 3rd line; teclistamab and elotuzumab-based options in the 4th line; and teclistamab, elranatamab, and belantamab mafodotin in the 5th line."

CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Hematological Malignancies • Hypertension • Metabolic Disorders • Multiple Myeloma • Renal Disease

Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin (ASH 2025) - P1/2 | "In summary, combination therapy with belantamab mafodotin and elotuzumab has shown an encouraging safety profile and a promising preliminary efficacy including among those with prior failure of BCMA-targeted therapy, as previously reported. 1 Our preliminary data suggest that decreased SLAMF7 density may predicts inferior clinical response among poor responders, likely representing one mechanism of escape while the impact on B-cell and T-cell compartments may contribute to disease response in patients with heavily pretreated RRMM. Funding and Product for this study was provided by GSK ."

Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • PD-1 • SDC1 • SLAMF7

Real-world outcomes with elotuzumab, lenalidomide, and dexamethasone in patients progressing on lenalidomide maintenance therapy: A single-center retrospective analysis (ASH 2025) - "The most common first-line regimen was lenalidomide, bortezomib, and dexamethasone (RVD), received by 24 patients (62%). The absence of OS differences by cytogenetic risk or clinical stage may reflect limited sample size. These findings underscore the clinical utility of EloRD in lenalidomide-exposed patients and support its continued integration into real-world RRMM treatment strategies."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Multiple Myeloma • SLAMF7

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting (ASH 2025) - "Among them, six received idecabtagene vicleucel and two received ciltacabtagene autoleucel...Two patients received pomalidomide monotherapy, and six received an elotuzumab-based combination regimen with either pomalidomide or lenalidomide, with or without dexamethasone, as maintenance therapy... Maintenance therapy following CAR T-cell infusion was associated with deepening of response in a subset of our patients (50%) with RRMM. However, the high incidence of infectious complications and hematologic toxicity highlights the need for careful patient selection and monitoring. These preliminary findings suggest that while maintenance may enhance disease control post–CAR T-cell therapy, the risk-benefit balance remains a critical consideration, and infectious complications are a particular concern."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Infectious Disease • Multiple Myeloma • Neutropenia • Respiratory Diseases • Targeted Protein Degradation • CRBN

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis (ASH 2025) - "All were refractory to daratumumab, bortezomib, cyclophosphamide, and pomalidomide; four were refractory to lenalidomide and belantamab mafodotin; one patient with t(11; 14) was refractory to venetoclax. Three relapsed after anti-BCMA academic CAR-T (HBI0101). Additional therapies included ixazomib (2), carfilzomib (1), elotuzumab (1), and melphalan (1)... Talquetamab produced deep and durable hematologic responses in heavily pretreated patients with R/R AL amyloidosis. Assessment of organ response potential was limited by irreversible organ dysfunction at baseline and short follow-up. Treatment was feasible, including in end-stage renal disease, and the safety profile was manageable without unexpected toxicities."

Clinical • Amyloidosis • Cardiovascular • Congestive Heart Failure • Dental Disorders • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Renal Disease • Septic Shock • Thrombocytopenia • Xerostomia

Race-related molecular differences in SLAMF7 expression drive disparities in multiple myeloma outcomes (ASH 2025) - "We identified a novel molecular mechanism underlying racial disparities in MM outcomes. AA patients demonstrate significantly higher SLAMF7 expression driven by differential Blimp-1-mediated transcriptional regulation due to a functional A>G polymorphism at position -742 of the SLAMF7 promoter. This polymorphism shows striking racial distribution differences, with AA patients predominantly carrying the A allele associated with increased SLAMF7 expression and potentially more aggressive disease."

IO biomarker • Hematological Malignancies • Multiple Myeloma • IL6 • PRDM1 • SLAMF7

Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark (ASH 2025) - "Consolidative high dose melphalan and autologousstem cell transplant (HDM/ASCT) after achieving an optimal hematologic response to L1 (N=17) wasincluded in L1...For 2L, 19 (34%) ptsreceived a venetoclax (VEN)-based regimen including VEN monotherapy, VEN-daratumumab, VEN-pomalidomide, VEN-bortezomib or VEN-bortezomib-daratumumab...Four received HDM/ASCT, while others had various combinations of daratumumab,bortezomib, ixazomib, carfilzomib, lenalidomide, pomalidomide, cyclophosphamide, elotuzumab,dapagliflozin and bendamustine.Hematologic responses to L2 included 15 (31%) CR, 12 (25%) VGPR, 8 (17%) low dFLC PR and 13 (27%) PRor less...Data from two additional sites will be added to the dataset by09/2025. These multicenter data will serve as a benchmark for new drug approval in the non-responderand relapsed setting."

Clinical • Amyloidosis

Journey of relapsed or refractory multiple myeloma (RRMM) after quadruple-class exposure (QCEx): Poor outcomes and high attrition (ASH 2025) - "Indextherapies were received between 2020 and 2024 in community (55%), academic (36%), or both settings(9%).The most common (≥5%) drug classes for the index therapy were GPRC5D bispecific antibody (BsAb; 13%), anti-BCMA (12%), chemo (11%), and PI+chemo (7%); for the first post-index LoT were anti-BCMA(30%), chemo (14%), IMiD+others (8%), and GPRC5D BsAb (6%); for the second post-index LoT were anti-BCMA (18%), chemo (11%), anti-BCMA+chemo (7%), GPRC5D BsAb (7%), PI+chemo (7%), PI+others (7%),and IMiD+others (7%); and for the third post-index LoT were anti-BCMA (17%), chemo (17%), PI+others(9%), and GPRC5D BsAb (9%).The most common (≥5%) agents were talquetamab (13%) and teclistamab (8%) for the index therapy; teclistamab (20%), talquetamab (6%), and elotuzumab+pomalidomide+dexamethasone (5%) for the firstpost-index LoT; teclistamab (11%) and talquetamab (7%) for the second post-index LoT; andciltacabtagene autoleucel (13%), talquetamab (9%), and..."

Hematological Malignancies • Multiple Myeloma

Evaluating the efficacy of montelukast in reducing the incidence and severity of monoclonal antibodies-associated infusion reactions (Phase II Study) (ASH 2025) - P2 | "Mean LDH was within normal limits (182 IU/L; range 99–451).A total of 198 MAB doses administered: Rituximab: 100(50.5%)Daratumumab: 42(21%)Obinutuzumab: 18(9%)Blinatumomab: 18(9%)Gemtuzumab: 14(7%)Elotuzumab: 6(3%)All patients received at least one cycle (Cycle 1), with rituximab being the most frequently used (21patients). Due to the low number of events, no significant associations wereidentified for reactions in Cycles 2–6.Compared to published registration trial data for the included MABs, adding MKA was associated with a43% risk reduction of infusion reactions (p < 0.001).Conclusion10 mg MKA added to the premedication of MAB infusion is well tolerated and significantly reduces therisk of MCAAEsPatients with a history of atopy or medication allergy are at high risk for infusion reactions during the firstcycle of therapy, even with MKA premedication. This subgroup may benefit from closer monitoring andfurther intervention strategies."

Clinical • P2 data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Burkitt Lymphoma • Chronic Lymphocytic Leukemia • CNS Disorders • Depression • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Immunology • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Psychiatry

Real-world comparative effectiveness of quadruplet vs triplet induction in multiple myeloma (ASH 2025) - "Adult patients (≥18years) with newly diagnosed multiple myeloma (ICD-10: C90.0) were identified between 2017 and 2024.Patients with relapsed/refractory disease or those treated with alkylators, thalidomide, pomalidomide, orelotuzumab were excluded to maintain parity. Two treatment cohorts were defined: triplet therapy(Bortezomib or Carfilzomib, Lenalidomide, Dexamethasone) and quadruplet therapy (Bortezomib orCarfilzomib, Lenalidomide, Dexamethasone, and Daratumumab)...In this large, multi-institutional real-world analysis, the addition of Daratumumab to triplet-basedinduction therapy significantly improved overall survival and reduced infectious complications in patientswith newly diagnosed multiple myeloma. These findings support the routine use of Daratumumab-basedquadruplet regimens as the preferred standard of care in eligible patients in real-world clinical practice.Additional studies are warranted to evaluate the long-term durability, toxicity profile, and..."

Clinical • HEOR • Real-world • Real-world evidence • Chronic Kidney Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Renal Disease • Septic Shock

Differences in insurer payments for hematology part B drugs between traditional Medicare and Medicare advantage (ASH 2025) - "Thelargest relative payment differences were observed for rituximab-pvvr (34.4% higher in MedicareAdvantage; 95% CI, 26.5% to 42.4%; p < 0.001), elotuzumab (31.4% higher in Medicare Advantage; 95% CI,0.1% to 62.8%; p < 0.001), and rituximab-abbs (31.4% higher in Medicare Advantage; 95% CI, 20.6% to42.2%; p < 0.001). Payment differences were the most similar between traditional Medicare and MedicareAdvantage for rituximab (3.1% higher in Medicare Advantage; 95% CI, -2.4% to 8.7%; p < 0.001) anddaratumumab (8.2% higher in Medicare Advantage; 95% CI, 0.6% to 15.8%; p < 0.001). While payments in traditional Medicare are well established, negotiated payments inMedicare Advantage are unknown and have implications for patient affordability and physician payment.We find that each drug in our sample is paid at a higher rate in Medicare Advantage than traditionalMedicare, suggesting that Medicare Advantage beneficiaries may be responsible for greater..."

Medicare • Reimbursement • US reimbursement • Hematological Disorders

Improved survival in patients with multiple myeloma over time: A retrospective single-center study focusing on patients aged 80 years and above (ASH 2025) - "Our analysis demonstrated that the Introduction of novel therapeutic agents has led to improved OSamong patients with MM, including both those aged <80 and ≥80 years. The favorable outcomesobserved in the later era likely reflect the increased use of novel agents—mainly daratumumab,isatuximab, carfilzomib, elotuzumab, and pomalidomide—which only became available in Japan after2015. Despite these advancements, MM-related mortality remains the leading cause of death."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Infectious Disease • Interstitial Lung Disease • Multiple Myeloma • Pneumonia • Renal Disease • Respiratory Diseases

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study (ASH 2025) - P1, P3 | "We report updated safety and efficacy results of Tal + Pomfrom MonumenTAL-2 with longer follow-up (~2 years). Pts had ≥2 prior lines of therapy (LOT), including a proteasome inhibitor and lenalidomide.Prior exposure to BsAbs, chimeric antigen receptor (CAR)-T cell therapy, and Pom was permitted...Prior treatment exposure included Pom (22.9%), BCMA CAR-T (8.6%), and BsAbs (2.9%); 65.7%were refractory to daratumumab... With longer follow up, Tal + Pom continued to show high, deep, and durable responses inpts with RRMM. The safety profile remained consistent with early treatment, with few additional dosemodifications or discontinuations observed in later cycles, highlighting the long-term tolerability of thisregimen. These findings support the rationale for the phase 3 MonumenTAL-6 study (NCT06208150),which compares the efficacy of Tal + Pom vs investigator's choice of elotuzumab + Pom + dexamethasoneor Pom + bortezomib + dexamethasone in pts with RRMM with 1–4..."

Clinical • Combination therapy • IO biomarker • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • CD8 • IFNG • TNFA

ALK+ LBCL and PBL share a similar plasmablastic transcriptional identity but show divergent signaling dependencies and therapeutic vulnerabilities (ASH 2025) - "While PBL and ALK+ LBCL share a similar transcriptionally plasmablastic phenotypeintermediate between DLBCL and PCM, they exhibit fundamentally different signaling dependencies.ALK+ LBCL is addicted to ALK-mediated STAT3 signaling and is highly sensitive to ALK-mediated STAT3degradation, whereas PBL is not dependent on STAT3 activation (even when harboring STAT3 activatingmutations), and instead demonstrates marked susceptibility to plasma cell-directed immunotherapies.These findings refine the biological classification of these lymphomas, identify new therapeutic targets,and support a shift away from DLBCL-based treatment paradigms toward more precise approachestailored to the unique biology of plasmablastic malignancies."

IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • ALK • NRAS • SLAMF7

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review (ASH 2023) - "Amongst trials that met primary endpoint showing improvement in PFS and clearly reported on +1q, the following drugs also improved PFS for those with +1q (when comparing hazard ratio (HR) for intervention versus control arm in the +1q subgroup): lenalidomide (len) maintenance in Myeloma XI, selinexor in BOSTON, and isatuximab in IKEMA and ICARIA...These included addition of carfilzomib in Myeloma XI, addition of carfilzomib vs bortezomib to len and dex for +1q (but not in Amp1q) in ENDURANCE, addition of elotuzumab to pomalidomide and dex, and bortezomib-based treatment before and after autologous stem cell transplantation (auto-SCT) vs no bortezomib (Table 2)...Important interventions for which subgroup analysis of +1q was not presented in trial results, and hence conclusions about the efficacy of the drugs specifically for patients with +1q cannot be ascertained included pomalidomide and ixazomib. Although subgroup analysis of various daratumumab trials has shown..."

Clinical • Review • Hematological Malignancies • Multiple Myeloma • Oncology

Unmet Needs in Multiple Myeloma and Potential Solutions: A Systemic Literature Review (ASH 2024) - "Other unmet needs reported were patient and family experience/supportive care (11%), pathophysiology (4%), diagnosis/response assessment (4%), toxicity management/prevention (3%) and poor prognosis (4%).Unmet needs that were reported starting from 2010 [and their proposed solutions] include treatment of high-risk cytogenetic features (4%) [elotuzumab/isatuximab/melflufen/selinexor/anti-BCMA conjugates], treatment of plasma cell leukemia/extramedullary disease (3%) [utilizing MM drugs (daratumumab/boretezemib/melfufen/frontline ASCT etc.)], prevention/management of toxicities (mucositis, neuropathy, nephropathy and GVHD) (1%) [CR4056/amifostine/cannabidiol], treatment/prevention of thromboembolism (1%) [risk assessment model for thromboembolism/studies on anticoagulation], treatment of frail/elderly (1%) [SEA BCMA/melflufen], immune response in MM (<1%) [immunological studies], and measures to assess response to treatment (<1%) [heavy light chain ratio/DW..."

Review • Geriatric Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Multiple Myeloma • Oncology • Orthopedics • Plasma Cell Leukemia • Renal Disease • Respiratory Diseases

Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant (ASH 2023) - "Of the therapies listed, 6 were adequately available in LIC and HIC: cyclophosphamide, lenalidomide, pomalidomide, daratumumab, bortezomib, and ASCT (Table 1)...Conclusion While most therapies were available, novel therapies such as isatuximab, ixazomib, selinexor, and elotuzumab were less readily accessible...The financial burden on healthcare is a major limiting factor. USMIRC plans to investigate potential solutions and pursue global collaborative efforts to reduce disparities in therapies."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Identification of therapeutic targets for giant cell arteritis through integrated analysis of multi-omics datasets. (PubMed, Hepatobiliary Pancreat Dis Int) - "This study provides a clinically-actionable atlas of 43 potential therapeutic targets in GCA, identifying novel mechanisms including autophagy modulation and metabolic reprogramming, with immediate drug repositioning opportunities and precision medicine strategies based on tissue-specific and cell-type-specific expression patterns. These findings require experimental validation before clinical translation."

IO biomarker • Journal • Giant Cell Arteritis • Immunology • Vasculitis • CTSS • ICAM1 • IL18 • IL6ST • SLAMF7 • TYMP • ULK1 • ULK3

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison (ASH 2023) - "Other therapies used to treat patients with multiple myeloma who have received at least one other therapy and are lenalidomide-refractory vary by country, but broadly include doublet and triplet regimens based on daratumumab, pomalidomide, bortezomib, and carfilzomib...Melflufen+d, PanVd, VenVd, PCd, IxaKd, D-monotherapy, V-monotherapy, CyVd, and DVCd were not of interest for the US, EU-5, the Netherlands, and Canada...Due to differences in methods for the comparisons versus ide-cel (KarMMa-3) and versus DKd, Kd, DVd, Vd, and Pd, these are reported separately... Cilta-cel demonstrated clinical benefit over EloPd, IsaPd, and SVd for response outcomes and PFS, highlighting its potential as an effective treatment option for patients with RRMM who have received at least one other therapy and are lenalidomide-refractory. These comparisons provide valuable information to contextualize the efficacy of cilta-cel in countries where treatment for these patients may be different..."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison (ASH 2024) - "Other therapies used to treat patients with multiple myeloma who have received at least one other therapy and are lenalidomide-refractory vary by country, but broadly include doublet and triplet regimens based on daratumumab, pomalidomide, bortezomib, and carfilzomib. In terms of response outcomes, patients in the cilta-cel arm demonstrated significantly superior ORR [vs IsaPd (RR : 1.39, 95% CI : 1.15-1.68; p= 0.0077), vs EloPd (RR : 1.53, 95% CI : 1.18-1.99; p= 0.0003) and vs SVd (RR : 1.24, 95% CI : 1.02-1.51; p= 0.0102)], ≥VGPR [vs IsaPd (RR : 2.52, 95% CI : 1.90-3.34; p<0.0001), vs EloPd (RR : 3.98, 95% CI : 2.36-6.72; p<0.0001) and vs SVd (RR : 2.26, 95% CI : 1.56-3.27; p<0.0001)] and ≥CR [vs IsaPd (RR : 17.36, 95% CI : 8.23-36.61; p<0.0001), vs EloPd (RR : 9.25, 95% CI : 3.93-21.80; p<0.0001) and vs SVd (RR : 8.10, 95% CI : 3.47-18.91; p<0.0001)] vs patients in all other comparators arms.Conclusion : In this comparative analysis, cilta-cel..."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

Medical Writing Bias in Myeloma Clinical Research: A Comprehensive Analysis (ASH 2023) - "Methods Clinical study papers from PubMed between January 2000 and March 2023 were analyzed if at least 1 of the 10 following drugs were evaluated: bortezomib (BORT), carfilzomib (CARF), daratumumab (DARA, elotuzumab (ELO), isatuximab (ISA), ixazomib (IXA), lenalidomide (LEN), panobinostat (PAN), pomalidomide (POM), and selinexor (SELI), and the manufacturer of the drug(s) sponsored the study (N=1466). Specific journals including Blood and British Journal of Haematology both show high numbers of papers with potential writing bias; and, furthermore, a high percentage of papers published in high impact journals such as the New England Journal of Medicine and Lancet show this type of potential bias. This practice of allowing medical writing to be carried out by those with direct ties to the pharmaceutical company is likely to result in the publication of papers with results and conclusions regarding the efficacy and safety of drugs that are biased which compromises their..."

Clinical • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology

XPORT-MM-031: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma (clinicaltrials.gov) - P3 | N=117 | Active, not recruiting | Sponsor: European Myeloma Network B.V. | Recruiting ➔ Active, not recruiting | N=222 ➔ 117

Enrollment change • Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology • CD4

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis (ASH 2024) - P3 | "The phase III DREAMM-7 study (NCT04246047) evaluated belantamab mafodotin (B), an antibody-drug conjugate targeting B-cell maturation antigen, with bortezomib (V)+dexamethasone (d; BVd) vs daratumumab (D)+Vd (DVd) in patients with RRMM who had ≥1 prior line of therapy (2L+) and included patients who were len-exposed/refractory (Hungria et al...NMAs were constructed based on the availability of regimen data within the networks for each subpopulation of interest (2L+ len-exposed, len-refractory, 2L-only and high-risk cytogenetic).Results : All regimens compared with BVd were PI-based regimens.The len-exposed subpopulation network comprised 8 RCTs and included the following regimens : BVd, DVd, carfilzomib (K)+ d (Kd; plus an alternative dosage), DKd, isatuximab (Isa)+ Kd (IsaKd), pomalidomide (P)+ Vd (PVd), selinexor (S)+Vd (SVd), and Vd...HRs (95% credible interval [CrI]) for BVd compared with anti-CD38 regimens included 0.34 (0.17-0.71) vs DKd, 0.29 (0.13-0.64) vs..."

IO biomarker • Retrospective data • Hematological Malignancies • Multiple Myeloma • Oncology

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) (ASH 2024) - P1/2, P3 | "Selinexor, an oral exportin 1 (XPO1) inhibitor approved in combination with dexamethasone (d) in penta-refractory MM and with d and bortezomib in RRMM after ≥1 prior therapy, is being evaluated with pomalidomide (P) and d (SPd) for the treatment of RRMM in the Phase 1b/2 STOMP trial (NCT02343042). Although the ORR was greater in the SPd60 cohort, TEAEs were less frequent, duration of exposure was longer, and higher dose intensity was achieved for patients treated with SPd40. These data support the further evaluation of low-dose weekly selinexor in the ongoing EMN29 trial (NCT05028348) of SPd40 versus elotuzumab and Pd in TCE RRMM progressing immediately after a αCD38-containing line of therapy."

Clinical • Anemia • Fatigue • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia • XPO1